VRCA — Verrica Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1660334 ·
Last close
$6.02
Market Cap
$103.42M
52W High
$8.50
52W Low
$4.24
ADV30
89,005
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,023,000 | 4,134,000 | -9,715,000 | -9,682,000 | 38,786,000 | 20,600,000 | 22,731,000 |
| Dec 2025 | 5,092,000 | 3,691,000 | -6,946,000 | -8,074,000 | 47,131,000 | 30,147,000 | 22,388,000 |
| Sep 2025 | 14,344,000 | 13,235,000 | 1,627,000 | -274,000 | 40,896,000 | 21,097,000 | 57,936,000 |
| Jun 2025 | 12,702,000 | 12,208,000 | 1,510,000 | 204,000 | 39,107,000 | 15,396,000 | 56,591,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,627,000
Investing CF
$-8,000
Financing CF
$1,445,000
CapEx
$-16,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.58
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-324,913,000
Inventory
$2,236,000
Receivables
$5,397,000
ST Investments
—
EBIT TTM
$-10,144,000
Pretax Income TTM
$-17,886,000
Interest Exp TTM
$7,742,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$37,161,000
EBITDA
$-13,058,000
Free Cash Flow
$-12,160,375
Enterprise Value
$84,945,440
Total Cash
$20,600,000
Total Debt
$1,442,000
Shares Out
17,178,786
Trailing EPS
$-1.10
Book Value
$1.44
ROE
—
ROA
-20.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,577,000 | -11,939,000 | -17,886,000 | 47,131,000 | 22,388,000 | — | -17,627,000 |
| Dec 2024 | 7,566,000 | -65,836,000 | -76,579,000 | 54,134,000 | 63,994,000 | — | -60,927,000 |
| Dec 2023 | 5,124,000 | -63,222,000 | -66,995,000 | 81,597,000 | 61,834,000 | — | -38,577,000 |
| Dec 2022 | 9,032,000 | -21,296,000 | -24,487,000 | 44,721,000 | 4,688,000 | — | -18,650,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-1,781,000
NetIncome TTM
$-22,860,000
OpCashFlow TTM
$0
Assets (Latest)
$54,134,000
Forward EPS
$-1.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $103.27M | $1.63 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $103.66M | $1.26 | — |
| ZOMDF | Zomedica Corp. | $102.40M | $0.10 | — |
| BMEA | Biomea Fusion, Inc. | $101.94M | $1.41 | — |
| RVRC | Revium Rx. | $101.42M | $1.67 | — |
News headlines (Yahoo Finance, 1h cache)
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-13 12:00 · Yahoo
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
2026-05-13 09:16 · Yahoo
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
2026-05-13 05:01 · Yahoo
Verrica Pharmaceuticals Q1 Earnings Call Highlights
2026-05-13 03:07 · Yahoo
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:15 · Yahoo
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-12 20:01 · Yahoo
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 19:15 · Yahoo
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA
2026-05-06 12:35 · Yahoo
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
2026-05-05 21:15 · Yahoo
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investiga
2026-05-05 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.